Mosquito Borne Diseases

Global Mosquito Borne Diseases Market to Reach US$4.6 Billion by 2030

The global market for Mosquito Borne Diseases estimated at US$3.2 Billion in the year 2024, is expected to reach US$4.6 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Malaria, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Dengue segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$881.8 Million While China is Forecast to Grow at 9.9% CAGR

The Mosquito Borne Diseases market in the U.S. is estimated at US$881.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$959.3 Million by the year 2030 trailing a CAGR of 9.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Mosquito Borne Diseases Market – Key Trends & Drivers Summarized

Why Are Mosquito Borne Diseases Still a Global Health Crisis?

Mosquito borne diseases continue to represent a significant global public health burden, particularly in tropical and subtropical regions. Diseases such as malaria, dengue fever, Zika virus, chikungunya, yellow fever, and West Nile virus are transmitted through the bites of infected Aedes, Anopheles, and Culex mosquitoes. These pathogens cause millions of infections annually and are responsible for substantial morbidity and mortality, particularly among children, the elderly, and immunocompromised individuals.

Despite advances in prevention and treatment, mosquito borne diseases persist due to climate change, urbanization, deforestation, and global travel—all of which expand mosquito habitats and transmission potential. Many of these diseases have no specific antiviral treatment or licensed vaccines, underscoring the importance of integrated vector control, early detection, and public health education in containing outbreaks. As disease vectors expand into previously non-endemic areas, the global threat level continues to rise.

What Innovations Are Improving Surveillance, Diagnosis, and Vector Control?

New approaches in vector surveillance, including AI-powered modeling, remote sensing, and GPS-enabled trap networks, are improving the real-time monitoring of mosquito populations and outbreak risks. Rapid diagnostic tests (RDTs), multiplex PCR platforms, and biosensor-based detection systems are enabling faster and more accurate diagnosis at point-of-care levels, particularly in remote and resource-limited settings.

In vector control, genetic engineering techniques such as sterile insect technology (SIT), Wolbachia-infected mosquito releases, and CRISPR-based gene drives are being tested to reduce mosquito fertility or block pathogen transmission. Next-generation insecticides with lower resistance potential, spatial repellents, and long-lasting insecticidal nets (LLINs) are also being deployed. Vaccine development pipelines—especially for dengue, malaria, and Zika—are progressing with candidates undergoing late-stage clinical trials or early regulatory approvals.

Which Regions and Health Systems Are Driving Demand for Disease Control and Intervention?

Sub-Saharan Africa and Southeast Asia remain the most affected regions, especially in relation to malaria and dengue, while Latin America, the Caribbean, and parts of the U.S. are seeing periodic outbreaks of Zika and chikungunya. Public health agencies, non-governmental organizations (NGOs), and global health alliances are key drivers of mosquito control programs and disease surveillance in endemic regions.

In high-income countries, the re-emergence of mosquito borne diseases due to climate shifts and increased travel is spurring investment in research, emergency preparedness, and vector control. International funding from organizations such as WHO, the Gates Foundation, and Gavi is helping expand vaccine access, R&D, and integrated disease management in vulnerable populations. Urban and semi-urban regions with inadequate sanitation and water management remain hot zones for transmission, necessitating focused public health interventions.

The Growth in the Mosquito Borne Diseases Market Is Driven by Several Factors…

The growth in the mosquito borne diseases market is driven by several factors including rising global temperatures, increased urbanization, and expanded travel and trade that facilitate mosquito proliferation and virus transmission. Advances in diagnostic technology, vector control methods, and genetically engineered solutions are expanding the toolset for managing outbreaks. Public health spending, international aid for disease elimination programs, and increased awareness are boosting demand for vaccines, vector monitoring tools, and insecticide products. As the geographic footprint of mosquito borne diseases continues to widen, the need for integrated prevention, surveillance, and therapeutic strategies is accelerating across both endemic and newly affected regions.

SCOPE OF STUDY:

The report analyzes the Mosquito Borne Diseases market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Disease Type (Malaria, Dengue, Yellow Fever, West Nile Virus, Chikungunya, Zika Virus, Other Disease Types); Treatment Type (Medication, Vaccination, Vector Control Methods, Immunotherapy, Supportive Care, Other Treatment Types); End-User (Hospitals, Clinics, Diagnostic Centers, Research Institutes, Government Organizations, NGOs, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• Abnova Corporation
• Bayer AG
• BioCryst Pharmaceuticals Inc.
• Clarke Environmental Mosquito Management
• CSL Limited
• Eisai Co., Ltd.
• Emergent BioSolutions
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• InBios International Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Oxitec Ltd
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• Takeda Pharmaceutical Company Limited
• Vestergaard

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more